EUCTR2008-008734-36-SK进行中（未招募）1 期
Efficacy and safety study of the antihistamine V00114CP 2.5 mg in the treatment of seasonal allergic rhinitis. Randomised, double-blind, three arm parellel group study including placebo and active control arm (levocetirizine 5 mg).
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with all the following criteria will be eligible for enrolment:
- •- male or female ambulatory patient,
- •- no less than 12 year-old (or no less than 18year-old according to National Legislation)
- •- suffering from a seasonal allergic rhinitis to grass and or weed pollen grain defined by :
- •- a documented medical history of seasonal rhinitis during the grass/weed pollen season
- •(mainly April to October) with symptoms (sneezing and/or palate itching and/or aqueous
- •rhinorrhea and/or nasal blockade) for at least two years; if, for a new patient, the medical
- •history has never been documented, the diagnosis will be assessed by the score for allergic
- •rhinitis (SFAR),
- •- a positive skin prick test at least to grass and or weed pollen grains, at selection visit or duly
- •documented in the medical file within the last 6 months,
- •- with a nasal symptomatology score rated by the patient equal or superior to 6 at inclusion
- •(maximal score: 12),
- •- willing and able to understand and sign an approved Informed Consent Form, and/or whose
- •parent(s) or guardian(s) has(have) given his/her(their) written consent for their child's
- •participation in the study,
- •- able to understand the protocol and to attend the control visits, and/or whose parent(s) or
- •guardian(s) is(are) cooperative with regard to compliance with study-related constraints,
- •- if required by national regulation, registered with a social security or health insurance system
- •and/or whose parent(s) or guardian(s) is(are) registered with a social security or health insurance
- •For girls/women of childbearing potential:
- •- use of an efficient contraceptive (implants, injectable, patch or combined oral contraceptives,
- •some intra-uterine devices for at least 2 months before the study and one month after the end of
- •- negative urine pregnancy test at selection visit
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with one of the following criteria will not be eligible for enrolment:
- •* Criteria related to pathologies
- •- Any cardio-vascular, renal, hepatic, gastro-intestinal, endocrine, haematological, neuropsychiatric
- •severe diseases that will not be compatible with the participation to the study in the
- •opinion of the investigator,
- •- Any acute or chronic disease that will not allow with the participation to the study in the
- •opinion of the investigator,
- •- Asthma requiring a corticosteroid treatment (GINA II and higher),
- •- Chronic alcoholism,
- •- History of agranulocytosis,
- •- Congenital galactosemia, malabsorption syndrome to glucose or galactose, or lactase deficiency,
- •- Seizure,
- •- Iatrogenic rhinitis,
- •- Nasal polyposis or severe deviation of the nasal septum,
- •- History of any nasal surgery within the last 6 months,
- •- Acute or chronic rhinosinusitis, as stated by the epidemiological definition of the EP3OS
- •- Upper respiratory tract infection within the last 3 weeks.
- •- Chronic neurologic or psychiatric diseases
- •* Criteria related to treatments
- •- Medical history of hypersensitivity to mequitazine or drug excipients,
- •- Medical history of hypersensitivity to levocetirizine, to other piperazine derivatives, or to any of
- •the excipients
- •- Severe renal impairment at less than 10 ml/min creatinine clearance
- •- Hereditary problems of galactose intolerance, glucose-galactose malabsorption, lactase
- •- Failure to a previous treatment with levocetirizine,
- •- Anti-allergy immunotherapy to grass and or weed pollens
- •- with increase of allergen challenges in the previous 2 years
- •- at any dose in the previous 6 months
- •- Depot corticosteroid treatment within the last 6 months,
- •- Oral, nasal, injectable (intramuscular, intravenous, intra-articular, intraspinal) corticosteroid
- •treatment within the last 4 weeks,
- •- Ocular, inhaled, potent or superpotent topical corticosteroid treatment within the last 2 weeks,
- •- Treatment by antileukotriene within the 7 days,
- •- Treatment by cromone or ketotifen within the last 1 week,
- •- Treatment by H1 antihistamine within the last 7 days, by loratadine within the last 10 days,
- •- Treatment by NSAIDs (other than oxicams) within the last 3 days,
- •- Treatment by oxicams within the last 7 days,
- •- Regular treatment by nasal or oral decongestive drug within the last 7 days,
- •- Treatment by CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine, thioridazine, clomipramine,
- •haloperidol),
- •- Treatment by tricyclic antidepressants (wash-out 4 weeks), MAO inhibitors (wash-out 4 weeks), atropine-like drugs (wash- out 4 weeks).
- •* Criteria related to the population
- •- length of QTc interval > 450 ms,
- •- planned travel outside the study area for a substantial portion of the study period,
- •- participation to another clinical trial in the previous month or during the study,
- •- patient who, in the judgement of the investigator is not likely to be compliant during the study,
- •or parent(s) or guardian(s) subject who, in the judgement of the investigator is/are not likely to be
- •compliant during the study,
- •- patient linguistically or psychologically unable to understand the information given or formulate
- •his/her informed consent or who refuses to give his/her consent in writing or parent(s) or
- 另有 3 项未显示
研究者
相似试验
进行中（未招募）
不适用
Efficacy and safety study of the antihistamine V0114CP 2.5mg in the treatment of seasonal allergic rhinitis randomized, double-blind, three arm parallel group study including placebo and active control arm (desloratadine 5 mg) - NDSeasonal allergic rhinitisMedDRA version: 9.1Level: LLTClassification code 10001723Term: Allergic rhinitisEUCTR2008-000133-22-ITPIERRE FABRE MEDICAMENT900
进行中（未招募）
不适用
EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIVE CONTROL ARM (DESLORATADINE 5 MG)to demonstrate the efficacy of a 2-week treatment by the antihistamine V0114CP 2.5 mg versus placebo in reducing symptoms during seasonal allergic rhinitis.EUCTR2008-000133-22-EEPierre Fabre Médicament900
进行中（未招募）
不适用
EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIVE CONTROL ARM (DESLORATADINE 5 MG)The medical condition to be investigated in this study is the seasonal allergic rhinitis. The intended indication for the product is the treatment of allergic rhinitisMedDRA version: 9.1Level: LLTClassification code 10039776Term: Seasonal allergic rhinitisEUCTR2008-000133-22-HUPierre Fabre Médicament900
进行中（未招募）
不适用
EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIVE CONTROL ARM (DESLORATADINE 5 MG)The medical condition to be investigated in this study is the seasonal allergic rhinitis. The intended indication for the product is the treatment of allergic rhinitisMedDRA version: 9.1Level: LLTClassification code 10039776Term: Seasonal allergic rhinitisEUCTR2008-000133-22-LTPierre Fabre Médicament900
进行中（未招募）
不适用
EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIVE CONTROL ARM (DESLORATADINE 5 MG)The medical condition to be investigated in this study is the seasonal allergic rhinitis. The intended indication for the product is the treatment of allergic rhinitisMedDRA version: 9.1Level: LLTClassification code 10039777Term: Seasonal rhinitisEUCTR2008-000133-22-BGPierre Fabre Médicament900